<DOCUMENT>
<TYPE>EX-10.182
<SEQUENCE>9
<FILENAME>a2104577zex-10_182.htm
<DESCRIPTION>EXHIBIT 10.182
<TEXT>
<HTML>
<HEAD>

</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#03WDC1176_8">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<!-- TOC_END -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="kp1177_exhibit_10.182"> </A>
<A NAME="toc_kp1177_1"> </A>
<BR></FONT><FONT SIZE=2><B>Exhibit&nbsp;10.182    <BR>  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kp1177_public_health_service_b__kp102457"> </A>
<A NAME="toc_kp1177_2"> </A>
<BR></FONT><FONT SIZE=2><B>PUBLIC HEALTH SERVICE    <BR>    <BR>    BIOLOGICAL MATERIALS LICENSE AGREEMENT    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is entered into between the Public Health Service ("PHS"), through the Office of Technology Transfer, National Institutes of Health, Box OTT,
Bethesda, Maryland 20892, U.S.A. and MedImmune&nbsp;Inc. ("LICENSEE"), a corporation of Delaware, having an office at 35 West Watkins Mill Road, Gaithersburg, Maryland. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;Definitions: </FONT></P>

<UL>
<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD><FONT SIZE=2>"Materials"
means the following biological materials: murine hybridoma cell lines designated as #1153, #1142, #1129, #1121, #1243, #1261-25, #1236-4,
#1228-28, #1224-1, #1219-22, #1175-40, #1113-44, and #1105-1 developed in the laboratory of Drs. Brian Murphy and Robert
Chanock.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD><FONT SIZE=2>"Licensed
Products" means monoclonal antibodies against respiratory syncytial virus.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD><FONT SIZE=2>"Net
Sales" means the total gross receipts by LICENSEE for sales, leasing, and renting of Licensed Products, whether invoiced or not, less returns and allowances actually granted,
rebates to the extent actually allowed, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in
amounts customary in the trade. No deductions shall be made for commissions paid to individuals, whether they be with independent sales agencies or regularly employed by LICENSEE, or for the cost of
collections. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;LICENSEE
wishes to obtain a license from PHS to use the Materials provided under this Agreement in its commercial research or product development and marketing
activities. LICENSEE represents that it has the facilities, personnel and expertise to use the Materials for commercial purposes and agrees to expend reasonable efforts and resources to develop the
Materials for commercial use and/or commercial research. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;PHS
hereby grants to LICENSEE a worldwide, non-exclusive license to make, have made and use the Materials and to make, have made, use and sell Licensed
Products. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;PHS
agrees to provide LICENSEE with samples of the Materials, excluding progeny, subclones and derivatives thereof, ("Supplied Materials"), as available, and at
reasonable cost to replace the Supplied Materials, as available, in the event of their unintentional destruction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;In
consideration of the grant in Paragraph&nbsp;3 above, LICENSEE hereby agrees to make the following payments to PHS: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD><FONT SIZE=2>Within
30&nbsp;days of its execution of this Agreement, a noncreditable, nonrefundable license issue royalty of (CONFIDENTIAL TREATMENT REQUESTED);
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD><FONT SIZE=2>A
nonrefundable minimum annual royalty of (CONFIDENTIAL TREATMENT REQUESTED) which shall be due and payable on January&nbsp;1, 1995 and on January&nbsp;1 of each calendar
thereafter, (CONFIDENTIAL TREATMENT REQUESTED) of which shall be full creditable against earned royalties due under paragraph&nbsp;5 (c)&nbsp;below in any year, provided, however, that no royalty
payment under paragraph&nbsp;5 (c)&nbsp;shall be reduced by more than (CONFIDENTIAL TREATMENT REQUESTED);
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD><FONT SIZE=2>An
earned royalty of (CONFIDENTIAL TREATMENT REQUESTED) of Net Sales for Licensed Products that contain Materials in whole or in part and (CONFIDENTIAL TREATMENT REQUESTED) on all
other Licensed Products, which shall be due and payable within sixty days of the end of each calendar year. </FONT></DD></DL>
</UL>
<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2104577",CP="MEDIMMUNE, INC.",DN="8",CHK=202412,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KP1177A.;3',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<UL>
<UL>
</UL>
</UL>
<UL>

<P><FONT SIZE=2>All
payments required under this Agreement shall be in U.S. Dollars, net of all non-U.S. taxes, and shall be made by check or bank draft drawn on a United States bank and made payable to
"NIH/Patent Licensing". All such payments shall be sent to the following address: NIH, P.O.&nbsp;Box 360120, Pittsburgh, Pennsylvania, 15251-6120. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;LICENSEE
agrees to make written reports to PHS within sixty (60)&nbsp;days after the end of each calendar year. This report shall state the number, description, and
aggregate Net Sales of Licensed Products sold, leased or rented by LICENSEE and the resulting calculation pursuant to Paragraph&nbsp;5 of payment due. LICENSEE shall submit each such report along
with payment due PHS for the calendar year covered by the report to PHS at the address listed in Paragraph&nbsp;5 above and shall also send a copy
of the report to PHS at the Mailing Address for Notices indicated on the Signature Page of this Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;LICENSEE
agrees to supply the laboratory of Drs. Murphy and Chanock (PHS) at no charge reasonable quantities, solely determined by LICENSEE, of Materials and Licensed
Products that LICENSEE offers for sale or otherwise makes available for public use. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall become effective on the date when the last party to sign has executed this Agreement and shall terminate twenty (20)&nbsp;years from this effective
date, unless previously terminated under the terms of Paragraphs 15 or 16 below. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;LICENSEE
agrees to retain control over the Materials, and not to distribute them to third parties without the prior written consent of PHS except as provided in
Paragraph&nbsp;3, except for use in making Licensed Products by LICENSEE. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;&nbsp;LICENSEE
agrees that this Agreement does not preclude PHS from distributing the Materials to third parties for research or commercial purposes. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;&nbsp;By
this Agreement, PHS grants no patent rights expressly or by implication to any anticipated or pending PHS patent applications or issued patents. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;&nbsp;NO
WARRANTIES, EXPRESS OR IMPLIED, ARE OFFERED AS TO THE MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF THE MATERIALS OR LICENSED PRODUCTS MAY BE EXPLOITED WITHOUT
INFRINGING THE PATENT RIGHTS OF ANY THIRD PARTIES. LICENSEE accepts license rights to the Materials and Licensed Products "as is", and PHS does not offer any guarantee of any kind. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;LICENSEE
agrees to indemnify and hold harmless the United States government from any third party claims, costs, damages or losses that may arise from or through
LICENSEE's use of the Materials or Licensed Products. LICENSEE further agrees that it will not by its action bring the United States government into any lawsuit involving the Materials or Licensed
Products. PHS shall provide LICENSEE written notification of any claims as soon as practicable after PHS has knowledge of such claims. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;LICENSEE
agrees in its use of any PHS-supplied materials to comply with all applicable statutes, regulations and guidelines, including Public Health Service
and PHS regulations and guidelines. LICENSEE agrees not to use the Materials for research involving human subjects or clinical trials in the United States without complying with 21 CFR Part&nbsp;50
and 45 CFR Part&nbsp;46. LICENSEE agrees not
to use the Materials for research involving human subjects or clinical trials outside of the United States without notifying PHS, in writing, of such research or trials and complying with the
applicable regulations of the appropriate national control authorities. Written notification to PHS of research involving human subjects or clinical trials outside of the United States shall be given
no later than sixty (60)&nbsp;days prior to commencement of such research or trials. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;&nbsp;LICENSEE
may terminate this Agreement upon sixty (60)&nbsp;days written notice to PHS. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;&nbsp;PHS
may terminate this Agreement if LICENSEE is in default in the performance of any material obligation under this Agreement, and if the default has not been remedied
within ninety (90)&nbsp;days after the date of written notice by PHS of such default. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2104577",CP="MEDIMMUNE, INC.",DN="8",CHK=136961,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KP1177A.;3',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<BR>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;&nbsp;Upon
termination of this Agreement, LICENSEE agrees to return all Materials to PHS, or provide PHS with certification of their destruction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;&nbsp;Within
ninety (90)&nbsp;days of termination of this Agreement, LICENSEE agrees to submit a final report to PHS, and to submit payment of any royalties due. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;&nbsp;LICENSEE
is encouraged to publish the results of its research projects using the Materials or Licensed Products. In all oral presentations or written publications
concerning the Materials or Licensed Products, LICENSEE will acknowledge the contribution of Drs. Murphy and Chanock and the PHS agency supplying the Materials, unless requested otherwise by PHS or
Drs. Murphy and Chanock. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;&nbsp;This
Agreement shall be construed in accordance with the laws of the United States as interpreted and applied by the Federal courts in the District of Columbia. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;&nbsp;This
Agreement constitutes the entire understanding of PHS and LICENSEE and supersedes all prior agreements and understandings with respect to the Materials. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;&nbsp;The
provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any
controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;&nbsp;Paragraphs
12, 13 and 19 of this Agreement shall survive termination of this Agreement. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2104577",CP="MEDIMMUNE, INC.",DN="8",CHK=678434,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KP1177A.;3',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kp1177_phs_biological_material__kp102352"> </A>
<A NAME="toc_kp1177_3"> </A>
<BR></FONT><FONT SIZE=2><B>PHS BIOLOGICAL MATERIALS LICNESE AGREEMENT    <BR>    <BR>    SIGNATURE PAGE    <BR>  </B></FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In Witness Whereof, the parties have executed this agreement on the dates set forth below. Any communication or notice to be given shall be forwarded to the
respective addresses listed below. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=2><FONT SIZE=2>FOR PHS:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>BARBARA M. MCGAREY J.D.</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Barbara M. McGarey J.D.</FONT></TD>
<TD WIDTH="50%" ALIGN="CENTER"><FONT SIZE=2><BR>
August&nbsp;24, 1994</FONT><HR NOSHADE><FONT SIZE=2> Date</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Deputy
Director, Office of Technology Transfer<BR>
National Institutes of Health </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="50%"><FONT SIZE=2>Mailing Address for Notices:</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2>Office of Technology Transfer<BR>
National Institutes of Health<BR>
Box OTT<BR>
Bethesda, Maryland 20892</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>FOR
LICENSEE (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of LICENSEE made or referred to in this Agreement are truthful and
accurate.) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="50%"><FONT SIZE=2><BR>
/s/&nbsp;&nbsp;</FONT><FONT SIZE=2>WAYNE T. HOCKMEYER</FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=2> Wayne T. Hockmeyer</FONT></TD>
<TD WIDTH="50%" ALIGN="CENTER"><FONT SIZE=2><BR>
June&nbsp;30, 1994</FONT><HR NOSHADE><FONT SIZE=2> Date</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>Chairman
and Chief Executive Officer </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="76%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="50%"><FONT SIZE=2>Mailing Address for Notices:</FONT></TD>
<TD WIDTH="50%"><FONT SIZE=2>MedImmune,&nbsp;Inc.<BR>
35 W. Watkins Mill Road<BR>
Gaithersburg, MD 20878</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2104577",CP="MEDIMMUNE, INC.",DN="8",CHK=948311,FOLIO='blank',FILE='DISK021:[03WDC7.03WDC1177]KP1177A.;3',USER='WAVILES',CD=';4-MAR-2003;11:35' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="03WDC1176_8">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2><A HREF="#toc_kp1177_1">Exhibit 10.182</A></FONT><BR>
</UL>
<FONT SIZE=2><A HREF="#toc_kp1177_2">PUBLIC HEALTH SERVICE BIOLOGICAL MATERIALS LICENSE AGREEMENT</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kp1177_3">PHS BIOLOGICAL MATERIALS LICNESE AGREEMENT SIGNATURE PAGE</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=YLEE,SEQ=,EFW="2104577",CP="MEDIMMUNE, INC.",DN="8" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
